From May 13 to 15, 2026, the 92nd National Pharmaceutical Fair (PHARMCHINA), themed "Building a New Ecosystem for Pharmaceutical Health, Innovation, and Co-development," grandly opened at the Shanghai National Exhibition and Convention Center. Amidst this industry event gathering thousands of pharmaceutical companies across the country, Sino Universal Pharma made a significant appearance with its full product matrix and strategic achievements, comprehensively showcasing its phased accomplishments in product pipelines, centralized procurement implementation, and international cooperation.
At the opening ceremony, Louis, Deputy General Manager of Sino Universal Pharma, was invited to attend the ribbon-cutting ceremony, jointly inaugurating the event with industry leaders and representatives of leading enterprises. This invitation represents authoritative industry recognition of Sino Universal Pharma's comprehensive strength, brand credibility, and market position.
Matrix Layout: A Dazzling Appearance
During this critical period of transition between old and new growth drivers in the pharmaceutical industry, Sino Universal Pharma has remained steadfast in upholding its corporate values of "striving, focus, value, and altruism." At the exhibition, we profoundly illustrated our dual-drive strategy of "global sourcing + self-driven R&D," showcasing the achievements of our four core product pipelines. A total of 37 approved products across 62 specifications and multiple upcoming projects made a collective appearance, comprehensively meeting the core demands of clinical diagnosis and treatment, primary healthcare, and public health consumption.
More than ten national centralized procurement and follow-up varieties made a collective appearance, covering core therapeutic areas such as cardiovascular and cerebrovascular diseases, digestion, neurology, and oncology specialty drugs. With comprehensive categories and reliable quality, these products provide partners with cost-effective, highly accessible solution options.
Core products such as Lansoprazole Orally Disintegrating Tablets, Tizanidine Hydrochloride Tablets, Teriflunomide Tablets, Fampridine Extended-Release Tablets, and Atazanavir Sulfate Capsules have become focal points of on-site engagement and cooperation, leveraging their advantages such as scarce dosage forms, first-to-market status, clinical necessity, and strong regulatory credentials.
During the exhibition, Sino Universal Pharma received significant attention and praise from numerous upstream enterprises and both new and long-standing partners. Together with the marketing team, the company's leadership engaged in in-depth discussions with domestic and international partners to align resources and needs, facilitating the precise integration of products with the market and strengthening a long-term, win-win collaborative ecosystem.
Joint Development, Witnessing the Brilliance Together
Since the partnership began in 2021, Xiluoshi® (Pantoprazole Sodium Enteric-Coated Tablets) was selected in the fourth round of national centralized procurement. By 2025, its market share had consistently ranked No. 1 in hospital channel sales for multiple consecutive years. As the partner accounting for the largest share of Sino Universal Pharma's single-product sales, Mr. ARVIND KUMAR CHANDAK, President of Aurobindo Greater China, visited the exhibition site for guidance and held a meeting with Mr. Li Wang, Chairman of Sino Universal Pharma. The two parties exchanged views on corporate development directions and agreed to continue building a core partnership based on aligned progress and deep joint cultivation in the future.
Shi Beishi® (Dapagliflozin Tablets) was successfully selected in the eleventh round of national centralized procurement. The product's excellent quality, combined with Sino Universal Pharma team's professional academic promotion capabilities, has earned dual recognition from both clinical practice and the market. Mr. SRIDHAR SUBRAMANIAN, President of Cipla Greater China, presented Sino Universal Pharma with the "2025-2026 Best Sales Excellence Award" on-site, highlighting his recognition of the company.
Mr. SATHEESHKUMAR SRIHARAN, General Manager of Dr. Reddy's Greater China, together with his core management team, visited the Sino Universal Pharma booth and held the 2027 fiscal year annual award ceremony, presenting the company with the "Best Partner Award." Sino Universal Pharma has now become Dr. Reddy's partner with the largest number of co-developed varieties in China. The award was given in recognition of the aligned vision and close collaboration between both parties, as well as to honor the company's key products and outstanding teams.
Innovation Leads, Building the Future
The successful conclusion of this Pharmaceutical Fair marks not only a comprehensive test of Sino Universal Pharma's product strength, channel capability, and service capacity, but also the starting point for the company to embark on a new industry cycle and begin a new journey.
Remaining true to its original aspiration and advancing with dedication, Sino Universal Pharma faces the new opportunities and challenges of normalized centralized procurement, high-quality industry development, and the expansion of primary healthcare. The company will continue to build a highly competent and specialized team, strengthen compliance operations, channel services, and global resource integration capabilities. It will further deepen strategic collaborations with international enterprises and accelerate the introduction of high-quality resources and localized implementation. By better responding to tiered diagnosis and treatment systems and the needs of primary healthcare, the company aims to enhance product accessibility and service coverage. Driven by both self-directed R&D innovation and global sourcing, Sino Universal Pharma will continue to solidify its product moat and contribute to industry upgrading.
Looking ahead, Sino Universal Pharma will remain focused on high-quality products as its core, supported by professional services, and will continue to deeply cultivate the pharmaceutical and healthcare sector, safeguard public health, and fully support the implementation of the Healthy China strategy.